Back to News
Market Impact: 0.5
Akeso Reports Positive Overall Survival Results For Ivonescimab In First-Line PD-L1-Positive NSCLC
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Akeso reported positive overall-survival results from the Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in first-line PD-L1-positive locally advanced or metastatic non-small cell lung cancer. The positive late-stage survival data strengthen ivonescimab's clinical profile in a major oncology indication and could support regulatory and commercial prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Trip.com swings to Q2 loss after $763 million antitrust penalty